Earnings call Cytokinetics transitioned to a global commercial-stage company in Q4 2025, driven by the FDA, EU, and China approvals and U.S. launch of MYQORZO. Full-year 2025 revenue surged to $88M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results